Irvine Scientific Company Description Irvine Scientific, a member of the JXTG Group, has been at the forefront of cell culture media development for more than 45-years. Possessing an unrivaled heritage of innovation, superior quality, and technical expertise, the company supplies the cell therapy, immunotherapy, biopharmaceutical, cytogenetic, and Assisted Reproductive Technologies (ART) industries with a range
of advanced cell culture media products and expert development, optimization, and commercial manufacturing services. Through the PRIME®-XV media platform, Irvine Scientific offers cell therapy clients specialized cell culture media solutions to support basic, translational, and clinical research using both stem cells and primary cells. Developed through a Quality by Design (QbD) approach, the platform is comprised of chemically-defined, serum-free formulations designed to minimize risk from adventitious agents and deliver consistent results. The platform is cGMP manufactured using raw materials from a strictly controlled supply chain and include document packets to facilitate regulatory submissions. As cell-based therapies frequently require media optimization or custom manufacturing, Irvine Scientific offers manufacturing services to produce custom formulations and custom packaging from 10-10,000L (liquid), or 1-7000 kg (dry powder). As the cell culture media partner of choice for cell therapy applications, Irvine Scientific delivers individualized service and unsurpassed customer support to overcome any challenge. With deep industry knowledge and extensive experience with cGMP manufacturing, medical media, global regulatory compliance, including ISO, IVD, and FDA regulations, the company can support the nuanced needs of the cell therapy community—from basic research through to scale-up and commercialization.